Endocare, Inc. Rejects Unsolicited Proposal From HealthTronics

IRVINE, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Endocare, Inc. announced today that its Board of Directors has unanimously rejected the unsolicited proposal from HealthTronics, Inc. to purchase all of the outstanding shares of Endocare for $2.28 per share. After careful evaluation, the Board determined that the proposal is inadequate and not in the best interests of Endocare's stockholders.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

CONTACT: Investor Contact, Matt Clawson, matt@allencaron.com, or Len Hall,
len@allencaron.com, both of Allen & Caron, Inc., +1-949-474-4300, both for
Endocare, Inc.; or For Additional Information, Craig T. Davenport, CEO, or
Michael R. Rodriguez, CFO, both of Endocare, Inc., +1-949-450-5400

Web site: http://www.endocare.com/

Back to news